Prevalence of urinary tract infections and antibiotic susceptibility among pregnant women

Original Research


Background: Urinary tract infection (UTI) is a health problem that must be taken care of during pregnancy. If not treated promptly, UTIs can progress to severe and leave unpredictable complications for both mother and fetus. Currently, in Vietnam, there are few studies on UTIs in pregnancy, especially on pathogens as well as their antibiotic susceptibility characteristics.

Objectives: This study was conducted to determine the bacteria rates among pregnant women with UTI symptoms and antibiotic resistance patterns.

Methods: In a cross-sectional survey, a total of 178 pregnant women at Thuan Kieu General Clinic from 05/2022 to 07/2022 were recruited. Urine from these patients was cultured on BA, MC, and CHROMagarTM Orientation.

Results: The infection ratio was 30.3%. The rate of Gram-positive cocci was 77.8%, and the rate of Gram-negative bacilli was 22.2%. Specifically, the highest proportion was the group of Staphylococcus coagulase negative with 26 samples at 46.3%; Staphylococcus aureus was isolated in all 8 samples at 14.8%; samples infected with Streptococci and Enterococci at 14.8% and 1.9%; 6 samples infected with E. coli with 11.1%; 4 samples infected by Acinetobacter sp with 7.4%; and the remaining were infected with Klebsiella sp with 3.7%. In addition, in the study, two samples of Staphylococci resistant to Methicillin were isolated at 3.7%. The rate of pathogenic bacteria resistant to the old single antibiotics of the β-lactam is high, while the combined antibiotics give good treatment efficiency with both negative and positive cultures.

Conclusion: The rate of UTI in pregnant women is 30.3%. Pathogens mainly found include Staphylococcus aureus, E. coli, Klebsiella sp, and Acinetobacter sp. E. coli is no longer the leading cause of UTIs. As a replacement, there was an increase in Gram-positive cocci as Staphylococci. Recommended antibiotics for UTIs are nitrofurantoin, and β-lactam antibiotics in combination, such as amoxicillin-clavulanate, and piperacillin-tazobactam.

Graphical abstract